- Home
- MSGS vs AXSM Comparison
MSGS vs AXSM Comparison
Compare MSGS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSGS
- AXSM
- Stock Information
- Founded
- MSGS 1879
- AXSM 2012
- Country
- MSGS United States
- AXSM United States
- Employees
- MSGS N/A
- AXSM N/A
- Industry
- MSGS Services-Misc. Amusement & Recreation
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- MSGS Consumer Discretionary
- AXSM Health Care
- Exchange
- MSGS Nasdaq
- AXSM Nasdaq
- Market Cap
- MSGS 4.9B
- AXSM 5.1B
- IPO Year
- MSGS N/A
- AXSM 2015
- Fundamental
- Price
- MSGS $197.82
- AXSM $121.28
- Analyst Decision
- MSGS Buy
- AXSM Strong Buy
- Analyst Count
- MSGS 5
- AXSM 16
- Target Price
- MSGS $253.60
- AXSM $176.56
- AVG Volume (30 Days)
- MSGS 204.4K
- AXSM 553.1K
- Earning Date
- MSGS 08-12-2025
- AXSM 08-04-2025
- Dividend Yield
- MSGS N/A
- AXSM N/A
- EPS Growth
- MSGS N/A
- AXSM N/A
- EPS
- MSGS N/A
- AXSM N/A
- Revenue
- MSGS $1,039,220,000.00
- AXSM $495,033,000.00
- Revenue This Year
- MSGS N/A
- AXSM $64.05
- Revenue Next Year
- MSGS $4.68
- AXSM $56.46
- P/E Ratio
- MSGS N/A
- AXSM N/A
- Revenue Growth
- MSGS 1.18
- AXSM 69.83
- 52 Week Low
- MSGS $173.26
- AXSM $75.56
- 52 Week High
- MSGS $237.99
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- MSGS 47.79
- AXSM 70.77
- Support Level
- MSGS $195.33
- AXSM $115.99
- Resistance Level
- MSGS $200.03
- AXSM $123.59
- Average True Range (ATR)
- MSGS 3.96
- AXSM 3.29
- MACD
- MSGS 0.13
- AXSM 1.24
- Stochastic Oscillator
- MSGS 57.93
- AXSM 88.56
About MSGS Madison Square Garden Sports Corp. (New)
Madison Square Garden Sports Corp owns and operates a portfolio of assets featuring some of the recognized sports teams, including the Knicks of the NBA and the Rangers of the NHL. It generates revenue from several sources: ticket sales and a portion of suite rental fees at The Garden and others. It has one operating and reportable segment and one reporting unit for goodwill impairment testing purposes.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.